Equillium posts new preclinical EQ504 data in ulcerative colitis at International AHR Conference

• Equillium disclosed new preclinical findings for EQ504 in ulcerative colitis ahead of two poster presentations at the 7th International AHR Conference.
• Results will be presented September 29 to October 2, 2026, in Porto, Portugal.
• Data point to improved intestinal barrier repair with reduced inflammatory signaling, supporting EQ504’s therapeutic rationale in ulcerative colitis.
• Separate work indicates immune rebalancing, with suppression of pro-inflammatory responses alongside enhancement of regulatory pathways linked to tissue repair.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291605PRIMZONEFULLFEED9836310) on September 29, 2026, and is solely responsible for the information contained therein.